Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sprimont – page 50

1 231 clinical trials in Sprimont, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sprimont at a glance
1 231
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 231 trials in Sprimont

Open in trial search

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Study Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:68Ga-FAPI-46
  • Sponsor:University Hospital Maastricht

Acute myeloid leukaemia

Not yet recruiting

Study on Cobicistat, Venetoclax, and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Dementia Alzheimer's type

Not yet recruiting

Study on the Safety and Effectiveness of PRI-002 for Patients with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:D-Prolyl-D-Threonyl-D-Leucyl-D-Histidyl-D-Threonyl-D-Histidyl-D-Asparaginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginine Amide Acetate
  • Sponsor:Prinnovation GmbH

Glioblastoma

Not yet recruiting

Study on Glioblastoma Recurrence: Comparing SonoCloud-9 with Carboplatin to Standard Treatments Lomustine or Temozolomide for Patients Undergoing Tumor Removal Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Carthera

Relapsing multiple sclerosis+2

Not yet recruiting

Study on Long-Term Safety of Tolebrutinib for Patients with Relapsing or Progressive Multiple Sclerosis

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Adenocarcinoma pancreas+4

Not yet recruiting

Study on the Safety and Effectiveness of GTAEXS617 for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Exscientia AI Limited

SARS-CoV-2 test positive

Not yet recruiting

Study on Montelukast for COVID-19 Patients at Higher Risk of Complications in the Community

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Montelukast
  • Sponsor:Universiteit Maastricht

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Colitis ulcerative

Not yet recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sprimont

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. The research explores alternative approaches to managing chronic proton pump inhibitor usage.

  • Medication De-prescribing Strategies
  • Digestive System Disorders
  • Treatment Optimization

This primary care investigation evaluates different therapeutic approaches, including on-demand medication use and alternative treatments, to improve patient outcomes while reducing long-term medication dependency.

02 Primary Care Innovation

Ground-breaking research examining the effectiveness of various approaches to managing reflux and heartburn symptoms in primary care settings. The study aims to establish more patient-centered treatment protocols.

  • Patient-Centered Care
  • Symptom Management
  • Treatment Alternatives

The research compares traditional medication reduction methods with innovative approaches, including the use of alginate-based alternatives.

03 Therapeutic Management

Clinical investigation focused on developing evidence-based deprescribing protocols for long-term medication users. The research evaluates multiple therapeutic strategies to identify optimal treatment pathways.

  • Clinical Effectiveness
  • Treatment Optimization
  • Patient Safety

This comparative study aims to establish the most effective and patient-friendly approach to reducing unnecessary long-term medication use while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.